Related Experiment Video

Updated: May 17, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Challenges in prevention, diagnosis and therapy of emerging fungal diseases. Aspergillosis: A case study

P U Sarma1, P V Sarma, T Madan

  • 1Centre for Biochemical Technology, Mall Road, 110007 Delhi, India.

Indian Journal of Clinical Biochemistry : IJCB
|October 30, 2012
PubMed

Insights

Pathogenic filamentous fungi pose a growing public health risk, especially with rising HIV and tuberculosis rates. Advances in genomics and proteomics offer new avenues for developing effective antifungal diagnostics and therapeutics.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Biomedical Research

Background:

  • Filamentous fungal infections are an increasing public health concern, exacerbated by conditions like HIV and tuberculosis.
  • Current antifungal drugs face limitations due to drug resistance and cytotoxic effects, hindering effective treatment.
  • A deeper understanding of fungal biology is crucial for developing novel antifungal strategies.

Purpose of the Study:

  • To highlight the challenges in developing new fungal therapeutics and diagnostics.
  • To explore the potential of genomics and proteomics in advancing antifungal measures.
  • To emphasize the need for understanding fungal biological mechanisms for improved disease management.

Main Methods:

  • Review of current challenges in antifungal drug development.
  • Exploration of technological advances in genomics and proteomics.
  • Analysis of biological mechanisms of fungal colonization, survival, and host invasion.

Main Results:

  • Genomics and proteomics offer significant potential for developing preventive and therapeutic strategies against fungal diseases.
  • Understanding fungal biological mechanisms is key to overcoming limitations of existing antifungal drugs.
  • New insights can lead to precise diagnostics and targeted therapies for a broad range of fungal infections.

Conclusions:

  • Technological advancements provide a promising outlook for combating fungal diseases.
  • Further research into fungal biology is essential for developing next-generation antifungal treatments.
  • Integrated approaches combining diagnostics, therapeutics, and prevention are needed for effective fungal disease management.
Keywords:
Fungal diseasesaspergillosisgenomicshost's susceptibilitypathogenesisproteomics

More Related Videos

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

Related Concept Videos

Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Fungal Phylum Ascomycota01:28

Fungal Phylum Ascomycota

Phylum Ascomycota, a major division within the subkingdom Dikarya, comprises a diverse range of fungal species, including both unicellular yeasts and filamentous molds such as Aspergillus and Penicillium. These fungi thrive in a variety of habitats, from aquatic ecosystems to terrestrial environments, playing crucial ecological and economic roles.Morphology and ReproductionThe defining characteristic of Ascomycetes, commonly referred to as sac fungi, is the ascus—a sac-like structure that...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Infection01:20

Infection

When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
Overview of Fungi01:29

Overview of Fungi

Fungi are a diverse group of eukaryotes more closely related to animals than other eukaryotes. Fungal cell walls comprise chitin, a polysaccharide that provides structural strength, and glucans, which contribute to flexibility and integrity. Other polysaccharides, such as mannans and galactosans, may supplement or replace chitin in some fungi. These adaptations, along with their preference for acidic environments and tolerance for high osmotic pressure, enable fungi to thrive in various...